DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 203567
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.
Summary for 203567
Tradename: | JUBLIA |
Applicant: | Bausch |
Ingredient: | efinaconazole |
Patents: | 9 |
Formulation / Manufacturing: | see details |
Generic Entry Opportunity Date for 203567
Generic Entry Date for 203567*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 203567
Suppliers and Packaging for NDA: 203567
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567 | NDA | Valeant Pharmaceuticals North America LLC | 0187-5400 | 0187-5400-02 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0187-5400-02) > 2 mL in 1 BOTTLE, WITH APPLICATOR |
JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567 | NDA | Valeant Pharmaceuticals North America LLC | 0187-5400 | 0187-5400-04 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0187-5400-04) > 4 mL in 1 BOTTLE, WITH APPLICATOR |
Paragraph IV (Patent) Challenges for 203567
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
JUBLIA | SOLUTION;TOPICAL | efinaconazole | 203567 | 2018-06-06 |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;TOPICAL | Strength | 10% | ||||
Approval Date: | Jun 6, 2014 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Jun 6, 2019 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | Start Trial | Patent Expiration: | Jul 8, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | Start Trial | Patent Expiration: | Oct 5, 2021 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS |
Complete Access Available with Subscription